jrbetsilog
2025-01-12   

NoneMajor retailers in UK and Ireland pull products associated with Conor McGregorjrbetsilog 。

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares Outstanding

Juniata-Southern Lehigh state football playoff game among 7 postponed due to wintry weatherProjections from Market Research Future estimate the electric motorcycle market could grow to approximately $17 billion by 2030. Considering that the market was valued at around $7 billion in 2021, this represents a compound annual growth rate of nearly 12%. Gas price increases, government subsidies, technological advancements, and concerns over climate change have driven this trend. It could be argued that electric motorcycle companies have also had an impact on consumer preferences, primarily by designing powerful and technologically advanced bikes that can rival motorcycles with internal combustion engines. One such company is Stark Future. Founded in 2020 in Barcelona, Stark Future has a presence in over 50 countries around the world, including the United States. At present, Stark Future has one primary model, the Stark VARG. The year 2024 was Stark Future's first full year of operation, so it's safe to assume most people aren't too familiar with the company. Here's what you need to know about Stark motorcycles, including who makes them and where they are built. Stark Future's production facility is located just outside of Barcelona — that is where Stark Motorcycles are designed, made, and assembled. Spanning 215,000 square feet across three floors, the plant houses production lines, research and development, design, sourcing, and logistics operations. Stark Future uses the latest robot hardware for assembly, while its research and development team employs computer-aided design (CAD) software, as well as modern technologies like virtual reality and 3D printing . The company also operates an in-house lab for testing materials and construction techniques. Stark Future has the capacity to manufacture 1,000 motorcycles on a monthly basis as of 2024, thanks to investments from Eicher Motors, Santander, and Big Bets. Eicher Motors, the parent company of Royal Enfield , holds a 10.35% equity stake in Stark Future, valued at over $50 million. Santander has contributed over $20 million, while Big Bets has extended a credit facility of over $28 million. Additionally, in November 2024, Stark Future formed a strategic partnership with the Chinese industrial 3D printing company Farsoon Technologies. In Swedish, the word "stark" means "strong" or "powerful," while "varg" translates to "wolf." The Stark VARG lives up to its name with a carbon fiber-housed 360V motor, delivering between 60 to 80 horsepower and 938 Nm of torque. Charging takes one to two hours, depending on the charger specifications, while the bike weighs 260 pounds. The base model price for the Stark VARG is $10,999, which positions it competitively against bikes like the Yamaha XE4 , for example. The Stark VARG seems to be performing well in the market, as Stark Future is on track to reach over $90 million in annual revenue by the end of 2024. Stark Future is expected to release its first road-legal models in 2025. CEO Anton Wass said his company is "now preparing to achieve the same penetration in significantly larger road categories, with motorcycle platforms with a non-comparable level of innovation."

HOUSTON, Dec. 04, 2024 (GLOBE NEWSWIRE) -- BridgingApps®, a program of Easter Seals Greater Houston, a 501(c)(3) non-profit organization, is partnering with Sentara Health Plans to create a revolutionary transition tool for children and youth with special health needs. Through this project, BridgingApps has created an online resource to assist Virginia families with children who have special health care needs access information to prepare and successfully help them transition to adulthood. The interactive tool, Virginia Youth2Adult , will empower youth with special health care needs to grow successfully into adulthood. Transition planning requires addressing many areas of need for a child with chronic health conditions, yet there is currently no simple method that tackles areas as wide ranging as health care to age appropriate social activities, independent living or employment in any meaningful way. Families will be able to use Virginia Youth2Adult to begin planning early, ask the right questions, and find resources on many areas of life as an adult. "BridgingApps is uniquely positioned to create an innovative, easy to use and sustainable online tool that will empower families to plan early, obtain assistance with the right questions to ask, and access current information to allow their children to live as fully participating members of our community," says Easter Seals Greater Houston's CEO Elise Hough. A focal point of Virginia Youth2Adult is the connection with BridgingApps' App Search Tool, a free online tool that allows users to find a variety of smartphone/tablet applications, or apps, to assist with many areas of transition, such as education, managing health information, and independent living. The database of apps is trialed and reviewed by therapists, special education teachers, experts, and special needs users and focuses on skill, rather than age or diagnosis. “Sentara Health Plans is proud to introduce the Virginia Youth2Adult website, in collaboration with BridgingApps, as an interactive tool designed to support youth and caregivers across Virginia,” said Randy Ricker, Medicaid Plan President and Vice President of Sentara Health Plans. “This comprehensive resource empowers all Virginians to actively participate in this critical life state, providing confidence and support as they navigate education, employment, health care and independent living for themselves and loved ones.” Earlier this year, BridgingApps created Sentara Health Plans’ Member Profile App Lists which transformed the way that their members manage their health decisions and develop important skillsets, ultimately improving their health and quality of life. BridgingApps will seek input from the local Easter Seals affiliate, organizations, and subject matter experts throughout Virginia to create this resource. Virginia Youth2Adult will be available in 2024 on a variety of platforms and distributed widely in Virginia with partners in the areas of health care, education, disability advocacy and housing. About BridgingApps BridgingApps, a program of Easter Seals Greater Houston, provides the access, education, and resources needed to effectively use mobile, touch-based devices to help people with disabilities communicate, exceed educational goals, and reach their fullest potential. BridgingApps includes a website, app reviews by therapists and special education teachers, a custom app search engine, assistive technology labs, training and certification options for parents, organizations and schools. For more information, visit www.bridgingapps.org . About Easter Seals Greater Houston Since 1947, Easter Seals of Greater Houston, Inc. has provided help, hope, and answers to Veterans, Service Members, children and adults with any type of disability, and the families who love them. The local non-profit is leading the way to 100% equity, inclusion, and access through essential resources and supports for every stage of life. Through therapy, training, education, and support services, Easter Seals Greater Houston creates life-changing solutions so that people with disabilities can live, learn, work, and play in our community. For more information, visit www.eastersealshouston.org . About Sentara Health Sentara Health , an integrated, not-for-profit health care delivery system, celebrates more than 130 years in pursuit of its mission - "we improve health every day." Sentara is one of the largest health systems in the U.S. Mid-Atlantic and Southeast, and among the top 20 largest not-for-profit integrated health systems in the country, with 30,000 employees, 12 hospitals in Virginia and Northeastern North Carolina, and the Sentara Health Plans division which serves more than 1 million members in Virginia and Florida. Sentara is recognized nationally for clinical quality and safety, and is strategically focused on innovation and creating an extraordinary health care experience for our patients and members. Sentara was named to IBM Watson Health's "Top 15 Health Systems" (2021, 2018), and was recognized by Forbes as a "Best Employer for New Grads" (2022), "Best Employer for Veterans" (2022, 2023), and "Best Employer for Women" (2020). About Sentara Health Plans Sentara Health Plans provides health plan coverage to nearly one million members in Virginia and Florida. Sentara Health Plans offers a full suite of commercial products including employee-owned and employer-sponsored plans, as well as Individual & Family Health Plans, Employee Assistance Programs and plans serving Dual-Eligible, Medicare, and Medicaid enrollees. Media Contacts: Easter Seals Greater Houston Public Relations Sadie Eckenrod seckenrod@eastersealshouston.org Sentara Corporate Communications & Public Relations news@sentara.comAfter a proposed constitutional amendment that would have given the Utah Legislature free rein to repeal or amend voter-approved ballot initiatives went up in flames earlier this year, Republican lawmakers are weighing how to, in their eyes, keep measures in check. Nothing is settled upon yet, but options range from raising the signature threshold for ballot measures to requiring 60% approval for some measures. After the Utah Supreme Court unanimously ruled in July that legislators could not repeal or rewrite voter-passed initiatives , Republican legislative leaders issued dire warnings that Utah would see a tsunami of ballot initiatives fueled by out-of-state money. Others warned of attempts to legalize recreational marijuana, gambling and expanding abortion. Lawmakers thought they had solved the issue during a special session in August, where they pushed through Amendment D , essentially reversing the court’s ruling and asserting their power to revise initiatives. But the plan was derailed when the justices struck Amendment D from the ballot , ruling the wording on the ballot was deceptive and lawmakers failed to publish the amendment in newspapers, as the Utah Constitution requires. Since constitutional amendments have to be ratified by voters in a general election, legislators cannot take another run at Amendment D until 2026, forcing Republican leaders to look for other options to keep control over lawmaking in the state. Groups considering launching an initiative, meantime, are keeping a close eye on the proposals, knowing that changes in the upcoming legislative session could dramatically impact the outlook for any 2026 initiative effort. Barbara Stallone, executive director of People4Utah, a group considering an initiative to create open, multi-party primaries with the top two vote-getters advancing to the general election, regardless of party, said her group is “committed to ensuring that Utahns retain their constitutional right to reform their government.” “Some of the proposals that we have heard about for the 2025 session appear to encroach on those rights,” she said. “We are following all of these proposals closely and will ensure that Utahns’ voices are heard throughout the legislative process.” (Rick Egan | The Salt Lake Tribune) Sen. Kirk Cullimore, R-Sandy, discusses the constitutional amendment over citizen initiatives after it passed the house and the Senate, on Wednesday, Aug. 21, 2024. Sen. Kirk Cullimore, R-Cottonwood Heights, the incoming Senate majority leader, told The Salt Lake Tribune that discussions are in the early stages and no plan has been settled upon, several options have been floated. The simplest tactic would be to increase the number of signatures initiative supporters have to gather to get a question on the ballot. Currently, that number is 8% of the number of registered voters at the time of the most recent election, meaning the number initiative backers will be shooting for will increase to about 148,000, up from the current requirement of 134,298 , with specific targets in at least 26 of the state’s 29 Senate districts. That is assuming legislators don’t push the bar higher. “Some of those options have been discussed,” Cullimore said. “My concern, without looking into this legally, is if that gets challenged, would the court see that as an undue burden on this [initiative] right?” If the courts think the Legislature has made it too hard to get an initiative approved, judges could see that as infringing on the public’s right to make law via the initiative process and strike it down. Of the 24 states that allow ballot initiatives, Utah has one of — if not the — most challenging signature requirements according to data from the National Conference of State Legislatures. Cullimore thinks there might be a better argument for requiring initiatives to win approval in a majority of legislative districts, rather than just a simple majority of voters. The logic, he said, is that for the Legislature to pass a law it needs support from a majority of the members representing their legislative districts. “That might carry more legal weight,” he said, “and might make the initiative more representative of Utah if there’s a requirement like that.”. In 2018, when voters approved three ballot initiatives — legalizing medical marijuana , expanding Medicaid for low-income Utahns and creating the non-partisan redistricting commission — all by relatively narrow margins. The Medicaid expansion initiative, which passed 53% to 47%, won support in a majority of legislative districts . The Better Boundaries initiative passed by just a few thousand votes and won a majority in just Salt Lake, Summit, Grand and Carbon counties. Another option is increasing the percentage of voters that would need to support an initiative from 50% to 60%. Rep. Jason Kyle, R-Huntsville, has previously sponsored legislation to require the 60% threshold on initiatives that require a tax increase. That bill passed the Utah House last year and stalled in the Senate. Cullimore said it’s possible it could be expanded beyond just tax issues. Eleven states require a supermajority for constitutional amendments or certain ballot measures . In the last election, for example, 57% of Florida voters supported an amendment dealing with abortion rights, but it fell short of the 60% mark needed for approval. In Utah, a constitutional amendment approved in 1998 requires a two-thirds majority to pass any ballot initiative limiting hunting. Part of the language that was a major selling point for the Legislature’s Amendment D was a ban on foreign interests spending money on Utah ballot initiatives. Rep. Candace Pierucci, R-Herriman, appears aiming to accomplish that goal with a bill file she has opened. Neither Kyle nor Pierucci responded to messages about their plans for the upcoming session. Other states that have ventured down that road have faced court challenges. In September, a federal judge in Ohio blocked that state’s prohibition on foreign influence of ballot initiatives, but in October the appeals court overturned that decision in a 2-1 ruling , meaning, at least for now, the ban is in place. Rep. Andrew Stoddard, D-Murray, has also opened a bill file to address initiatives. He said his bill, while still being drafted, would lower the signature requirement and ban “dark money” — funds spent on campaigns whose donors are not reported — from the process. (Jeffrey D. Allred | Pool) Attorney Tyler Green speaks to the court as Mormon Women for Ethical Government and the League of Women Voters oppose the Utah State Legislature during oral arguments at the Utah Supreme Court in Salt Lake City on Wednesday, Sept. 25, 2024. Status of the gerrymandering lawsuit As lawmakers try to sort out how they plan to respond to the Utah Supreme Court’s ballot initiative ruling, the case that precipitated it — over 2018′s Proposition 4 which sought to prohibit partisan gerrymandering — is now in the hands of a lower court judge. After Better Boundaries’ initiative was approved by voters in 2018, the Legislature passed SB200 , which made the independent redistricting commission created under the bill simply advisory and removed a restriction on drawing legislative and congressional boundaries to favor one party and disadvantage another. The League of Women Voters, Mormon Women for Ethical Government and several voters sued , arguing that the congressional boundaries the Legislature adopted intentionally disadvantaged voters in Salt Lake County, one of the few somewhat liberal bastions in the state. In July, the Utah Supreme Court ruled that by undoing the core of the Better Boundaries Initiative, lawmakers essentially deprived voters of their constitutional right to enact ballot initiatives that reform government — prompting the Legislature’s attempt to amend the constitution to make ballot initiatives subject to repeal or amendment by lawmakers. The court said that, if the Legislature wants to substantially impair a voter-passed initiative, lawmakers need a compelling interest and the change must be narrowly tailored and sent the case back to a lower court judge to decide if the state met its burden. In a court filing last month attorneys for the Legislature argued that portions of the Better Boundaries initiative are unconstitutional, alleging they infringe on the Legislature’s right to create political boundaries, among other reasons. “The State has compelling interests in ensuring that its laws are constitutional, that all Utahns are represented in the redistricting process, that redistricting plans are enacted in a timely fashion, and that the State’s fiscal health isn’t jeopardized by prolonged litigation cost and mountainous attorney’s fees,” attorneys for the Legislature wrote. The plaintiffs’ lawyers responded in a brief filed just before the Thanksgiving holiday arguing that voters have been deprived of the nonpartisan gerrymandering that they voted for in 2018 and urged the court to move quickly and order the maps to be redrawn. “Utahns deserve to vote under lawful maps drawn according to the standards they adopted in enacting Prop 4 six years ago, and the Court should expeditiously conduct remedial proceedings to ensure that a lawful map is in effect for the 2026 election,” they wrote. Editor’s note • This story is available to Salt Lake Tribune subscribers only. Thank you for supporting local journalism.

Related hot word search:

Previous: j-lobesto
Next: